<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22096523</article-id><article-id pub-id-type="pmc">3214043</article-id><article-id pub-id-type="publisher-id">10-PONE-CT-20126</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0027108</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Clinical Trial</subject><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Clinical Research Design</subject><subj-group><subject>Clinical Trials</subject></subj-group></subj-group><subj-group><subject>Pulmonology</subject><subj-group><subject>Asthma</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Cost-Effectiveness of Internet-Based Self-Management Compared with Usual Care in Asthma</article-title><alt-title alt-title-type="running-head">Internet-Based Asthma Self-Management</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>van der Meer</surname><given-names>Victor</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>&#x0002a;</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>van den Hout</surname><given-names>Wilbert B.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bakker</surname><given-names>Moira J.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Rabe</surname><given-names>Klaus F.</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sterk</surname><given-names>Peter J.</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Assendelft</surname><given-names>Willem J. J.</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kievit</surname><given-names>Job</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sont</surname><given-names>Jacob K.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><collab>on behalf of the SMASHING (Self-Management in Asthma Supported by Hospitals, ICT, Nurses and General Practitioners) Study Group</collab></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Department of Medical Decision Making, Leiden University Medical Center, Leiden, The Netherlands</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Department of Respiratory Medicine, Academic Medical Center, Amsterdam, The Netherlands</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Semple</surname><given-names>Malcolm Gracie</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">University of Liverpool, United Kingdom</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>v.van_der_meer@lumc.nl</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: VM WBH KFR PJS WJJA JK JKS. Performed the experiments: VM MJB JKS. Analyzed the data: VM WBH JKS. Contributed reagents/materials/analysis tools: VM WBH MJB JK JKS. Wrote the paper: VM WBH MJB KFR PJS WJJA JK JKS.</p></fn></author-notes><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>11</day><month>11</month><year>2011</year></pub-date><volume>6</volume><issue>11</issue><elocation-id>e27108</elocation-id><history><date date-type="received"><day>16</day><month>6</month><year>2010</year></date><date date-type="accepted"><day>10</day><month>10</month><year>2011</year></date></history><permissions><copyright-statement>van der Meer et al.</copyright-statement><copyright-year>2011</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Effectiveness of Internet-based self-management in patients with asthma has been shown, but its cost-effectiveness is unknown. We conducted a cost-effectiveness analysis of Internet-based asthma self-management compared with usual care.</p></sec><sec><title>Methodology and Principal Findings</title><p>Cost-effectiveness analysis alongside a randomized controlled trial, with 12 months follow-up. Patients were aged 18 to 50 year and had physician diagnosed asthma. The Internet-based self-management program involved weekly on-line monitoring of asthma control with self-treatment advice, remote Web communications, and Internet-based information. We determined quality adjusted life years (QALYs) as measured by the EuroQol-5D and costs for health care use and absenteeism. We performed a detailed cost price analysis for the primary intervention. QALYs did not statistically significantly differ between the Internet group and usual care: difference 0.024 (95&#x00025; CI, &#x02212;0.016 to 0.065). Costs of the Internet-based intervention were $254 (95&#x00025; CI, $243 to $265) during the period of 1 year. From a societal perspective, the cost difference was $641 (95&#x00025; CI, $&#x02212;1957 to $3240). From a health care perspective, the cost difference was $37 (95&#x00025; CI, $&#x02212;874 to $950). At a willingness-to-pay of $50000 per QALY, the probability that Internet-based self-management was cost-effective compared to usual care was 62&#x00025; and 82&#x00025; from a societal and health care perspective, respectively.</p></sec><sec><title>Conclusions</title><p>Internet-based self-management of asthma can be as effective as current asthma care and costs are similar.</p></sec><sec><title>Trial Registration</title><p>Current Controlled Trials <ext-link ext-link-type="uri" xlink:href="http://www.controlled-trials.com/ISRCTN79864465/ISRCTN79864465">ISRCTN79864465</ext-link>
</p></sec></abstract><counts><page-count count="8"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Asthma is a chronic, inflammatory disorder of the airways clinically characterized by respiratory symptoms such as wheeze, cough, dyspnoea, chest tightness and impaired lung function <xref rid="pone.0027108-National1" ref-type="bibr">[1]</xref>, <xref rid="pone.0027108-National2" ref-type="bibr">[2]</xref>. Treatment for asthma is aimed at improving asthma control, i.e. reducing current symptoms and need for short-acting bronchodilation, improving lung function and preventing future exacerbations <xref rid="pone.0027108-National1" ref-type="bibr">[1]</xref>&#x02013;<xref rid="pone.0027108-Taylor1" ref-type="bibr">[3]</xref>.</p><p>In the past decade, the care for asthma patients has shifted from physician-managed care to guided self-management. Guided self-management includes asthma education, self-monitoring of symptoms and/or lung function and adjustment of treatment according to an action plan guided by a health care professional (not necessarily a physician). Self-management has been shown to improve asthma control and quality of life and reduce health care utilization and sometimes improve lung function <xref rid="pone.0027108-Gibson1" ref-type="bibr">[4]</xref>.</p><p>Besides clinical effectiveness, the implementation of new disease management strategies requires an economic evaluation to determine whether the clinical benefits are gained at reasonable costs. Several cost evaluations have compared paper-and-pencil self-management plans to usual care in asthma <xref rid="pone.0027108-Willems1" ref-type="bibr">[5]</xref>&#x02013;<xref rid="pone.0027108-Willems2" ref-type="bibr">[11]</xref>, but only a few compared costs to quality of life <xref rid="pone.0027108-Schermer1" ref-type="bibr">[10]</xref>&#x02013;<xref rid="pone.0027108-Willems2" ref-type="bibr">[11]</xref>. Most of these economic evaluations found that written self-management plans for asthma were likely to be cost-effective compared to usual physician provided care. However, the implementation of paper-and-pencil self-management plans is hampered by patients' and doctors' reluctance to use written diaries <xref rid="pone.0027108-Jones1" ref-type="bibr">[12]</xref>.</p><p>Implementation of guided self-management programs may be enhanced by the use of Internet-based technologies, particularly in remote and underserved areas. In a recently conducted randomized controlled trial we have shown that Internet-based self-management is feasible and provides better clinical outcomes compared to usual physician provided care with regard to asthma related quality of life, asthma control, symptom-free days and lung function <xref rid="pone.0027108-VanderMeer1" ref-type="bibr">[13]</xref>. Although previous trials have also evaluated the clinical effects of Internet-based self-management in adults <xref rid="pone.0027108-Rasmussen1" ref-type="bibr">[14]</xref> and children <xref rid="pone.0027108-Chan1" ref-type="bibr">[15]</xref>, <xref rid="pone.0027108-Jan1" ref-type="bibr">[16]</xref>, so far, no economic evaluations have been conducted. We therefore carried out a cost-utility analysis, comparing quality of life with societal and health care costs during one year, to determine whether the clinical benefits gained with Internet-based self-management are attained at reasonable costs.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><p>The protocol for this trial and supporting CONSORT checklist are available as supporting information; see <xref ref-type="supplementary-material" rid="pone.0027108.s001">Protocol S1</xref>, <xref ref-type="supplementary-material" rid="pone.0027108.s002">Checklist S1</xref>, and <xref ref-type="supplementary-material" rid="pone.0027108.s003">Flowchart S1</xref>.</p><sec id="s2a"><title>Ethics statement</title><p>The study was approved by the Medical Ethics Committee of the Leiden University Medical Center. All participants gave their written consent.</p></sec><sec id="s2b"><title>Setting and Participants</title><p>Two hundred patients participated in a 12-month multicenter, non-blinded, randomized controlled trial. Patients were recruited from 37 general practices (69 General Practitioners) in the Leiden and The Hague area and the Outpatient Clinic of the Department of Pulmonology at the Leiden University Medical Center, The Netherlands over the period from September 2005 to September 2006 <xref rid="pone.0027108-VanderMeer1" ref-type="bibr">[13]</xref>. We included patients with physician diagnosed asthma as coded according to the International Classification of Primary Care in the electronic medical record <xref rid="pone.0027108-Lamberts1" ref-type="bibr">[17]</xref>, aged 18&#x02013;50 years, with a prescription of inhaled corticosteroids for at least three months in the previous year, access to Internet at home, mastery of the Dutch language and without serious comorbid conditions that interfered with asthma treatment. Patients on maintenance oral glucocorticosteroid treatment were excluded. All participants gave their written consent.</p><p>Details of the randomization and intervention have been described previously <xref rid="pone.0027108-VanderMeer1" ref-type="bibr">[13]</xref>. Briefly, the 200 patients were randomly assigned to Internet-based self-management as an adjunct to usual care (Internet group: 101 patients) or to usual physician-provided care alone (usual care group: 99 patients). Allocation took place by computer after collection of the baseline data, ensuring concealment of allocation. The Internet-based self-management program included weekly monitoring of asthma control and lung function, immediate treatment advice according to a computerized personal action plan after completing the validated Asthma Control Questionnaire on the Internet <xref rid="pone.0027108-Juniper1" ref-type="bibr">[18]</xref>, on-line education and group-based education, and remote Web communication with a specialized asthma nurse.</p></sec><sec id="s2c"><title>Utilities and QALYs</title><p>Utilities express the valuation of health-related quality of life on a scale from zero (death) to one (perfect health). Patients described their health-related quality of life using the EuroQol classification system (EQ-5D) <xref rid="pone.0027108-The1" ref-type="bibr">[19]</xref>, from which we calculated their utilities over time using the British tariff <xref rid="pone.0027108-Dolan1" ref-type="bibr">[20]</xref>. The area under the utility curve is known as quality-adjusted life years (QALY) and was used as the primary outcome measure for the cost-effectiveness analysis. Patients additionally valued their own health status on a visual analogue scale (VAS). This scale from the patient perspective is potentially more responsive to change than other generic quality of life instruments, but is not the best choice for economic evaluations from a societal perspective <xref rid="pone.0027108-RuttenvanMlken1" ref-type="bibr">[21]</xref>. The VAS scale was transformed to a utility scale using the power transformation 1&#x02212;(1-VAS/100)<sup>1.61</sup>
<xref rid="pone.0027108-Stiggelbout1" ref-type="bibr">[22]</xref>.</p><p>We obtained utility measurements at baseline, 3 and 12 months. For EQ-5D measurements 6.5&#x00025;, 10&#x00025; and 8.5&#x00025; were missing and for visual analogue measurements 7&#x00025;, 10&#x00025; and 9&#x00025; were missing at 0, 3 and 12 months, respectively. To correct for possibly selective non-response, missing measurements were replaced by 5 imputed values based on switching regression <xref rid="pone.0027108-Briggs1" ref-type="bibr">[23]</xref>, <xref rid="pone.0027108-VanBuuren1" ref-type="bibr">[24]</xref> with regression variables randomisation group, age, sex, asthma control at baseline and available utility measures at all time points.</p></sec><sec id="s2d"><title>Costs</title><p>We distinguished three major cost categories: intervention costs, other health care costs and productivity costs <xref rid="pone.0027108-Schermer1" ref-type="bibr">[10]</xref>, <xref rid="pone.0027108-Willems2" ref-type="bibr">[11]</xref>. Intervention costs consisted of materials (software support, electronic spirometer), personnel and patient costs (travel, time, Internet and text messaging costs). Other health care costs included contacts (including face-to-face, telephonic and home contacts) with health care professionals (general practitioners, chest physician, other specialists, physiotherapists, psychologists, complementary care and other paramedical professionals), emergency room visits, hospital admissions and both asthma and non-asthma medication. Productivity costs consisted of hours of absence from work.</p><p>Patients reported their use of health care resources and the hours of absence from work using a quarterly cost-questionnaire. We used Dutch standard prices for units of resource use (contacts with health care professionals, hospital admissions and drug prescriptions) and hours of absenteeism, designed to represent societal costs and to standardize economic evaluations <xref rid="pone.0027108-Oostenbrink1" ref-type="bibr">[25]</xref>, <xref rid="pone.0027108-Dutch1" ref-type="bibr">[26]</xref>. Hours of absenteeism were converted to costs by multiplying them with the age and gender average hourly wage <xref rid="pone.0027108-Oostenbrink1" ref-type="bibr">[25]</xref>. Details of the drugs used were derived from pharmacy records. All prices were converted to the price level of 2007 according the general Dutch consumer price index <xref rid="pone.0027108-Statistics1" ref-type="bibr">[27]</xref> and converted to US dollars using the purchasing power parity index (&#x020ac;1&#x0200a;=&#x0200a;$1.131) <xref rid="pone.0027108-OECD1" ref-type="bibr">[28]</xref>. Because of the one-year time horizon, costs were not discounted.</p><p>Cost-questionnaires were scheduled to be handed in at 3, 6, 9 and 12 months. Of these quarterly questionnaires, 10&#x00025;, 14&#x00025;, 19&#x00025; and 9&#x00025; were missing, respectively. Pharmacy records were available for 182 patients (91&#x00025;). Missing cost-questionnaire and pharmacy record were imputed using multiple imputation, as previously described under &#x02018;Utilities and QALYs&#x02019;.</p></sec><sec id="s2e"><title>Statistical Analysis</title><p>Differences and statistical uncertainty of QALYs and costs were calculated using non-parametric bootstrap estimation with 5000 random samples (1000 from each of the 5 imputations). Differences in costs resulted from differences in volumes rather than differences in unit costs, since we used standard prices for units of resource use and hours of absenteeism. We estimated the intervention effect by a linear regression model with randomisation group as only independent variable, combining the 5 multiple imputation sets using Rubin's rules <xref rid="pone.0027108-Rubin1" ref-type="bibr">[29]</xref>.</p><p>Analyses were carried out with Stata 9.0 (StataCorp, College Station, TX).</p></sec><sec id="s2f"><title>Cost-Effectiveness Analysis</title><p>The base case cost-effectiveness analysis compared societal costs with QALYs gained based on the British EQ-5D over the period of one year. Because of the limited degree of modeling in this cost utility analysis, we carried out sensitivity analyses only on the use of different utility measures (British EQ-5D or Visual Analogue Scale) and on the included cost categories (societal or healthcare perspective).</p><p>Statistical uncertainty of the cost-effectiveness was analyzed using the net benefit approach <xref rid="pone.0027108-Stinnett1" ref-type="bibr">[30]</xref>. The net benefit is defined as &#x003bb; x &#x00394;QALY &#x02013; &#x00394;costs, where &#x003bb; is the willingness to pay for a gain of one quality-adjusted life year. This way, the observed QALY difference is reformulated into a monetary difference. The uncertainty about cost-effectiveness was graphically shown by plotting the bootstrapped incremental costs and QALY estimates in the cost-effectiveness plane (200 estimated pairs for each of the 5 imputed datasets) (<xref ref-type="fig" rid="pone-0027108-g001">figure 1</xref>). In a cost-effectiveness acceptability curve we graphed the probability (1&#x02212;[one sided] P value) that the Internet-based self-management program was cost-effective (i.e. had higher net benefit) compared with usual care, as a function of &#x003bb; for a range of &#x003bb; between 0 and 200000 (<xref ref-type="fig" rid="pone-0027108-g002">figure 2</xref>). We highlighted this probability at commonly cited willingness-to-pay values of $50000 and $100000 per QALY <xref rid="pone.0027108-Eichler1" ref-type="bibr">[31]</xref>.</p><fig id="pone-0027108-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0027108.g001</object-id><label>Figure 1</label><caption><title>Cost-effectiveness planes.</title><p>Uncertainty about cost-effectiveness of the asthma internet-based self-management program compared with usual asthma care (showing the 1000 bootstrapped estimates). Circles and triangles represent the incremental societal and health care costs, respectively, plotted against the incremental quality adjusted life years (QALY) (intervention minus usual care). The south-east quadrant indicates that internet-based self-management intervention dominates usual care (i.e. effectiveness is higher and costs are lower), the north-west quadrant indicates that usual care dominates the intervention. The points below the dashed diagonal lines are cost-effective at a willingness to pay threshold of $50000 and $100000 per QALY, respectively.</p></caption><graphic xlink:href="pone.0027108.g001"/></fig><fig id="pone-0027108-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0027108.g002</object-id><label>Figure 2</label><caption><title>Cost-effectiveness acceptability curves.</title><p>The probability that Internet-based self-management is cost-effective compared to usual care depending on the willingness-to-pay per QALY from a societal perspective <italic>(solid line)</italic> and health care perspective <italic>(dashed line)</italic>.</p></caption><graphic xlink:href="pone.0027108.g002"/></fig></sec></sec><sec id="s3"><title>Results</title><p>The Internet group and usual care group consisted of 101 and 99 participants, respectively. Mean age of the sample was 37 years and 70&#x00025; of the participants were women (<xref ref-type="table" rid="pone-0027108-t001">table 1</xref>). At baseline, asthma related quality of life, asthma control and medication use were similar for the two randomization groups.</p><table-wrap id="pone-0027108-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0027108.t001</object-id><label>Table 1</label><caption><title>Baseline characteristics.</title></caption><alternatives><graphic id="pone-0027108-t001-1" xlink:href="pone.0027108.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Usual Care Group(n&#x0200a;=&#x0200a;99)</td><td align="left" rowspan="1" colspan="1">Internet Group(n&#x0200a;=&#x0200a;101)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Women,</td><td align="left" rowspan="1" colspan="1">71&#x00025;</td><td align="left" rowspan="1" colspan="1">68&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, years</td><td align="left" rowspan="1" colspan="1">37 (18&#x02013;50)</td><td align="left" rowspan="1" colspan="1">36 (19&#x02013;50)</td></tr><tr><td align="left" rowspan="1" colspan="1">Asthma duration, years</td><td align="left" rowspan="1" colspan="1">18 (0&#x02013;47)</td><td align="left" rowspan="1" colspan="1">15 (1&#x02013;47)</td></tr><tr><td align="left" rowspan="1" colspan="1">Education level</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">14&#x00025;</td><td align="left" rowspan="1" colspan="1">11&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1">Middle</td><td align="left" rowspan="1" colspan="1">33&#x00025;</td><td align="left" rowspan="1" colspan="1">37&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1">High</td><td align="left" rowspan="1" colspan="1">53&#x00025;</td><td align="left" rowspan="1" colspan="1">52&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1">Care provider</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">General practitioner</td><td align="left" rowspan="1" colspan="1">80&#x00025;</td><td align="left" rowspan="1" colspan="1">79&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1">Chest physician</td><td align="left" rowspan="1" colspan="1">20&#x00025;</td><td align="left" rowspan="1" colspan="1">21&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1">FEV<sub>1</sub> (pre-bronchodilator), L</td><td align="left" rowspan="1" colspan="1">3.13 (1.56&#x02013;5.23)</td><td align="left" rowspan="1" colspan="1">3.08 (1.14&#x02013;5.19)</td></tr><tr><td align="left" rowspan="1" colspan="1">FEV<sub>1</sub> (pre-bronchodilator), &#x00025; predicted</td><td align="left" rowspan="1" colspan="1">90 (53&#x02013;118)</td><td align="left" rowspan="1" colspan="1">88 (34&#x02013;133)</td></tr><tr><td align="left" rowspan="1" colspan="1">Inhaled corticosteroid dose, &#x000b5;g/day</td><td align="left" rowspan="1" colspan="1">517 (0&#x02013;2000)</td><td align="left" rowspan="1" colspan="1">494 (0&#x02013;1000)</td></tr><tr><td align="left" rowspan="1" colspan="1">Inhaled long-acting &#x003b2;<sup>2</sup>-agonist, &#x00025; of patients</td><td align="left" rowspan="1" colspan="1">60&#x00025;</td><td align="left" rowspan="1" colspan="1">59&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1">Leukotriene modifier, &#x00025; of patients</td><td align="left" rowspan="1" colspan="1">2&#x00025;</td><td align="left" rowspan="1" colspan="1">3&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1">Clinical outcomes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Asthma Quality of Life Questionnaire<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref>
</td><td align="left" rowspan="1" colspan="1">5.79 (3.03&#x02013;7.00)</td><td align="left" rowspan="1" colspan="1">5.73 (3.66&#x02013;6.94)</td></tr><tr><td align="left" rowspan="1" colspan="1">Asthma Control Questionnaire<xref ref-type="table-fn" rid="nt103">&#x02020;</xref>
</td><td align="left" rowspan="1" colspan="1">1.11 (0&#x02013;3.86)</td><td align="left" rowspan="1" colspan="1">1.12 (0.07&#x02013;3.22)</td></tr><tr><td align="left" rowspan="1" colspan="1">Patient utilities<xref ref-type="table-fn" rid="nt104">&#x02021;</xref>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">EQ-5D utility</td><td align="left" rowspan="1" colspan="1">0.89 (&#x02212;0.06&#x02013;1.00)</td><td align="left" rowspan="1" colspan="1">0.91 (0.49&#x02013;1.00)</td></tr><tr><td align="left" rowspan="1" colspan="1">EQ-5D visual analogue scale</td><td align="left" rowspan="1" colspan="1">74 (35&#x02013;100)</td><td align="left" rowspan="1" colspan="1">73 (20&#x02013;100)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>Data are mean (range) unless otherwise indicated.</p></fn><fn id="nt102"><label/><p>&#x0002a;Range 1 (worst) &#x02013; 7 (best) <xref rid="pone.0027108-The1" ref-type="bibr">[19]</xref>.</p></fn><fn id="nt103"><label>&#x02020;</label><p>Range 0 (best) &#x02013; 6 (worst) <xref rid="pone.0027108-Juniper1" ref-type="bibr">[18]</xref>.</p></fn><fn id="nt104"><label>&#x02021;</label><p>EQ-5D&#x0200a;=&#x0200a;EuroQol questionnaire, 5 dimensions <xref rid="pone.0027108-Dolan1" ref-type="bibr">[20]</xref>. Parts of this table were published previously <xref rid="pone.0027108-VanderMeer1" ref-type="bibr">[13]</xref>.</p></fn></table-wrap-foot></table-wrap><sec id="s3a"><title>Utilities and QALYs</title><p>At baseline, the utilities according to the EQ-5D did not statistically significantly differ between the Internet group and the usual care group. EQ-5D utilities did not reach a statistical significant difference throughout the study. At 3 months and 12 months the difference in EQ-5D utility was 0.037 (95&#x00025; CI, &#x02212;0.007 to 0.081) and 0.006 (95&#x00025; CI, &#x02212;0.042 to 0.054), respectively. Similarly, the difference in quality adjusted life years was not statistically significant: 0.024 (95&#x00025; CI, &#x02212;0.016 to 0.065) (<xref ref-type="table" rid="pone-0027108-t002">table 2</xref>).</p><table-wrap id="pone-0027108-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0027108.t002</object-id><label>Table 2</label><caption><title>Utilities at 0, 3 and 12 months and QALYs<xref ref-type="table-fn" rid="nt105">&#x0002a;</xref>.</title></caption><alternatives><graphic id="pone-0027108-t002-2" xlink:href="pone.0027108.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Variable</td><td align="left" rowspan="1" colspan="1">Usual Care Group</td><td align="left" rowspan="1" colspan="1">Internet Group</td><td align="left" rowspan="1" colspan="1">Difference (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">P value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">EQ-5D</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">0 months</td><td align="left" rowspan="1" colspan="1">0.89</td><td align="left" rowspan="1" colspan="1">0.91</td><td align="left" rowspan="1" colspan="1">0.026 (&#x02212;0.024 to 0.076)</td><td align="left" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" rowspan="1" colspan="1">3 months</td><td align="left" rowspan="1" colspan="1">0.89</td><td align="left" rowspan="1" colspan="1">0.93</td><td align="left" rowspan="1" colspan="1">0.037 (&#x02212;0.007 to 0.081)</td><td align="left" rowspan="1" colspan="1">0.099</td></tr><tr><td align="left" rowspan="1" colspan="1">12 months</td><td align="left" rowspan="1" colspan="1">0.91</td><td align="left" rowspan="1" colspan="1">0.92</td><td align="left" rowspan="1" colspan="1">0.006 (&#x02212;0.042 to 0.054)</td><td align="left" rowspan="1" colspan="1">0.80</td></tr><tr><td align="left" rowspan="1" colspan="1">QALYs</td><td align="left" rowspan="1" colspan="1">0.90</td><td align="left" rowspan="1" colspan="1">0.92</td><td align="left" rowspan="1" colspan="1">0.024 (&#x02212;0.016 to 0.065)</td><td align="left" rowspan="1" colspan="1">0.25</td></tr><tr><td align="left" rowspan="1" colspan="1">Visual analogue scale<xref ref-type="table-fn" rid="nt106">&#x02020;</xref>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">0 months</td><td align="left" rowspan="1" colspan="1">0.87</td><td align="left" rowspan="1" colspan="1">0.86</td><td align="left" rowspan="1" colspan="1">&#x02212;0.013 (&#x02212;0.045 to 0.019)</td><td align="left" rowspan="1" colspan="1">0.43</td></tr><tr><td align="left" rowspan="1" colspan="1">3 months</td><td align="left" rowspan="1" colspan="1">0.87</td><td align="left" rowspan="1" colspan="1">0.89</td><td align="left" rowspan="1" colspan="1">0.012 (&#x02212;0.026 to 0.050)</td><td align="left" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" rowspan="1" colspan="1">12 months</td><td align="left" rowspan="1" colspan="1">0.88</td><td align="left" rowspan="1" colspan="1">0.89</td><td align="left" rowspan="1" colspan="1">0.013 (&#x02212;0.015 to 0.040)</td><td align="left" rowspan="1" colspan="1">0.37</td></tr><tr><td align="left" rowspan="1" colspan="1">QALYs</td><td align="left" rowspan="1" colspan="1">0.88</td><td align="left" rowspan="1" colspan="1">0.88</td><td align="left" rowspan="1" colspan="1">0.007 (&#x02212;0.017 to 0.032)</td><td align="left" rowspan="1" colspan="1">0.57</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt105"><label/><p>&#x0002a;Values are summary estimates of the 5 data sets obtained by multiple imputation, combined using Rubin's rules.</p></fn><fn id="nt106"><label>&#x02020;</label><p>Transformed using the power transformation 1&#x02212;(1-VAS/100)<sup>1.61</sup>
<xref rid="pone.0027108-Briggs1" ref-type="bibr">[23]</xref>.</p></fn></table-wrap-foot></table-wrap><p>Visual analogue scale utilities were not statistically significantly different throughout the study. At 3 and 12 months the difference in visual analogue scale utility was 0.012 (95&#x00025; CI, &#x02212;0.026 to 0.050) and 0.013 (95&#x00025; CI, &#x02212;0.015 to 0.040), respectively. The difference in quality of life years based on the visual analogue scale was estimated to be 0.007 (95&#x00025; CI, &#x02212;0.017 to 0.032) (<xref ref-type="table" rid="pone-0027108-t002">table 2</xref>).</p></sec><sec id="s3b"><title>Costs</title><p>The total intervention costs were estimated at $25675, which is $254 (95&#x00025; CI, $243 to $265) per patient (<xref ref-type="table" rid="pone-0027108-t003">table 3</xref>). The highest cost components of the Internet-based intervention were software support ($7917) and the patients' time costs ($5380 for monitoring time and $5106 for attending the education sessions).</p><table-wrap id="pone-0027108-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0027108.t003</object-id><label>Table 3</label><caption><title>Implementation costs ($) of Internet-based self-management intervention.</title></caption><alternatives><graphic id="pone-0027108-t003-3" xlink:href="pone.0027108.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Component of cost</td><td align="left" rowspan="1" colspan="1">Cost per unit</td><td align="left" rowspan="1" colspan="1">Number of units</td><td align="left" rowspan="1" colspan="1">Total cost</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Materials</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">software support</td><td align="left" rowspan="1" colspan="1">7917/yr</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">7917</td></tr><tr><td align="left" rowspan="1" colspan="1">electronic spirometer</td><td align="left" rowspan="1" colspan="1">19.22/device</td><td align="left" rowspan="1" colspan="1">101</td><td align="left" rowspan="1" colspan="1">1942</td></tr><tr><td align="left" rowspan="1" colspan="1">Personnel</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">development educational aids</td><td align="left" rowspan="1" colspan="1">26/hr</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">412</td></tr><tr><td align="left" rowspan="1" colspan="1">education sessions</td><td align="left" rowspan="1" colspan="1">26/hr</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">780</td></tr><tr><td align="left" rowspan="1" colspan="1">data review and patient communication</td><td align="left" rowspan="1" colspan="1">26/hr</td><td align="left" rowspan="1" colspan="1">91</td><td align="left" rowspan="1" colspan="1">2351</td></tr><tr><td align="left" rowspan="1" colspan="1">Patient costs</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">travel costs for sessions</td><td align="left" rowspan="1" colspan="1">6/session</td><td align="left" rowspan="1" colspan="1">258</td><td align="left" rowspan="1" colspan="1">1465</td></tr><tr><td align="left" rowspan="1" colspan="1">time costs for sessions (incl. travel time)</td><td align="left" rowspan="1" colspan="1">20/session</td><td align="left" rowspan="1" colspan="1">258</td><td align="left" rowspan="1" colspan="1">5106</td></tr><tr><td align="left" rowspan="1" colspan="1">time costs for monitoring<xref ref-type="table-fn" rid="nt107">&#x0002a;</xref>
</td><td align="left" rowspan="1" colspan="1">0.50/log in</td><td align="left" rowspan="1" colspan="1">10873</td><td align="left" rowspan="1" colspan="1">5380</td></tr><tr><td align="left" rowspan="1" colspan="1">Internet log in costs<xref ref-type="table-fn" rid="nt108">&#x02020;</xref>
</td><td align="left" rowspan="1" colspan="1">0.0016/log in</td><td align="left" rowspan="1" colspan="1">9374</td><td align="left" rowspan="1" colspan="1">15</td></tr><tr><td align="left" rowspan="1" colspan="1">mobile phone costs<xref ref-type="table-fn" rid="nt109">&#x02021;</xref>
</td><td align="left" rowspan="1" colspan="1">0.20/message</td><td align="left" rowspan="1" colspan="1">1499</td><td align="left" rowspan="1" colspan="1">305</td></tr><tr><td align="left" rowspan="1" colspan="1">Total implementation costs</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">25675</td></tr><tr><td align="left" rowspan="1" colspan="1">Total implementation costs per patient</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">254</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt107"><label/><p>&#x0002a;Monitoring time was estimated at 3 minutes per log in and valued at $10 per hour, i.e. the Dutch standard price for unpaid labour <xref rid="pone.0027108-Statistics1" ref-type="bibr">[27]</xref>. Number of units was obtained from Internet log files.</p></fn><fn id="nt108"><label>&#x02020;</label><p>Internet costs were valued at $23 per month.</p></fn><fn id="nt109"><label>&#x02021;</label><p>Mobile phone costs were valued at $0.20 per message.</p></fn></table-wrap-foot></table-wrap><p>The difference in other health care costs was not statistically significant: $-217 (95&#x00025; CI, $&#x02212;1117 to $682) (<xref ref-type="table" rid="pone-0027108-t004">table 4</xref>). Patients in the Internet group had fewer contacts with physiotherapists ($&#x02212;120, p&#x0200a;=&#x0200a;0.03), but not with other health care providers, e.g. general practitioners ($&#x02212;69, p&#x0200a;=&#x0200a;0.18). Similarly differences in costs for medication did not reach statistical difference (<xref ref-type="table" rid="pone-0027108-t004">table 4</xref>). The difference in total health care costs was negligible: $37 (95&#x00025; CI, $&#x02212;874 to $950).</p><table-wrap id="pone-0027108-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0027108.t004</object-id><label>Table 4</label><caption><title>Average health care costs and societal costs per patient ($).</title></caption><alternatives><graphic id="pone-0027108-t004-4" xlink:href="pone.0027108.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">Usual Care Group</td><td colspan="2" align="left" rowspan="1">Internet Group</td><td colspan="2" align="left" rowspan="1">Difference</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Volume</td><td align="left" rowspan="1" colspan="1">Costs</td><td align="left" rowspan="1" colspan="1">Volume</td><td align="left" rowspan="1" colspan="1">Costs</td><td align="left" rowspan="1" colspan="1">Costs</td><td align="left" rowspan="1" colspan="1">P Value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Intervention costs</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">254</td><td align="left" rowspan="1" colspan="1">254</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Other health care costs</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">General practitioner<xref ref-type="table-fn" rid="nt110">&#x0002a;</xref>
</td><td align="left" rowspan="1" colspan="1">12.2</td><td align="left" rowspan="1" colspan="1">294</td><td align="left" rowspan="1" colspan="1">10.0</td><td align="left" rowspan="1" colspan="1">225</td><td align="left" rowspan="1" colspan="1">&#x02212;69</td><td align="left" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" rowspan="1" colspan="1">Chest physician</td><td align="left" rowspan="1" colspan="1">0.9</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">0.6</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">&#x02212;21</td><td align="left" rowspan="1" colspan="1">0.20</td></tr><tr><td align="left" rowspan="1" colspan="1">Other specialist</td><td align="left" rowspan="1" colspan="1">2.5</td><td align="left" rowspan="1" colspan="1">167</td><td align="left" rowspan="1" colspan="1">2.3</td><td align="left" rowspan="1" colspan="1">155</td><td align="left" rowspan="1" colspan="1">&#x02212;12</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Physiotherapist</td><td align="left" rowspan="1" colspan="1">8.6</td><td align="left" rowspan="1" colspan="1">234</td><td align="left" rowspan="1" colspan="1">4.2</td><td align="left" rowspan="1" colspan="1">114</td><td align="left" rowspan="1" colspan="1">&#x02212;120</td><td align="left" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">Psychologist</td><td align="left" rowspan="1" colspan="1">1.1</td><td align="left" rowspan="1" colspan="1">161</td><td align="left" rowspan="1" colspan="1">1.2</td><td align="left" rowspan="1" colspan="1">180</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">0.78</td></tr><tr><td align="left" rowspan="1" colspan="1">Complementary care</td><td align="left" rowspan="1" colspan="1">1.4</td><td align="left" rowspan="1" colspan="1">87</td><td align="left" rowspan="1" colspan="1">1.2</td><td align="left" rowspan="1" colspan="1">75</td><td align="left" rowspan="1" colspan="1">&#x02212;12</td><td align="left" rowspan="1" colspan="1">0.66</td></tr><tr><td align="left" rowspan="1" colspan="1">Other paramed. professionals</td><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">0.8</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">&#x02212;19</td><td align="left" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" rowspan="1" colspan="1">Emergency room</td><td align="left" rowspan="1" colspan="1">0.3</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">0.2</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">&#x02212;10</td><td align="left" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">Day admissions</td><td align="left" rowspan="1" colspan="1">0.3</td><td align="left" rowspan="1" colspan="1">92</td><td align="left" rowspan="1" colspan="1">0.3</td><td align="left" rowspan="1" colspan="1">86</td><td align="left" rowspan="1" colspan="1">&#x02212;6</td><td align="left" rowspan="1" colspan="1">0.88</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospitalizations</td><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">589</td><td align="left" rowspan="1" colspan="1">1.4</td><td align="left" rowspan="1" colspan="1">571</td><td align="left" rowspan="1" colspan="1">&#x02212;17</td><td align="left" rowspan="1" colspan="1">0.95</td></tr><tr><td align="left" rowspan="1" colspan="1">Drugs<xref ref-type="table-fn" rid="nt111">&#x02020;</xref>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Short-acting &#x003b2;2-agonists</td><td align="left" rowspan="1" colspan="1">54&#x00025;</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">50&#x00025;</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">&#x02212;8</td><td align="left" rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Inhaled corticosteroids (ICS)</td><td align="left" rowspan="1" colspan="1">50&#x00025;</td><td align="left" rowspan="1" colspan="1">89</td><td align="left" rowspan="1" colspan="1">52&#x00025;</td><td align="left" rowspan="1" colspan="1">77</td><td align="left" rowspan="1" colspan="1">&#x02212;12</td><td align="left" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Long-acting &#x003b2;2-agonists (LABA)</td><td align="left" rowspan="1" colspan="1">10&#x00025;</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">11&#x00025;</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">&#x02212;6</td><td align="left" rowspan="1" colspan="1">0.67</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Combination ICS&#x0002b;LABA</td><td align="left" rowspan="1" colspan="1">55&#x00025;</td><td align="left" rowspan="1" colspan="1">264</td><td align="left" rowspan="1" colspan="1">71&#x00025;</td><td align="left" rowspan="1" colspan="1">345</td><td align="left" rowspan="1" colspan="1">82</td><td align="left" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Leukotriene antagonists</td><td align="left" rowspan="1" colspan="1">8&#x00025;</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">23&#x00025;</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Oral corticosteroids</td><td align="left" rowspan="1" colspan="1">12&#x00025;</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">13&#x00025;</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">&#x02212;1</td><td align="left" rowspan="1" colspan="1">0.50</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Non-asthma medication</td><td align="left" rowspan="1" colspan="1">99&#x00025;</td><td align="left" rowspan="1" colspan="1">312</td><td align="left" rowspan="1" colspan="1">97&#x00025;</td><td align="left" rowspan="1" colspan="1">285</td><td align="left" rowspan="1" colspan="1">&#x02212;27</td><td align="left" rowspan="1" colspan="1">0.71</td></tr><tr><td align="left" rowspan="1" colspan="1">Subtotal other health care costs</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2518</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2300</td><td align="left" rowspan="1" colspan="1">&#x02212;217</td><td align="left" rowspan="1" colspan="1">0.63</td></tr><tr><td align="left" rowspan="1" colspan="1">Total health care costs</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2518</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2555</td><td align="left" rowspan="1" colspan="1">37</td><td align="left" rowspan="1" colspan="1">0.94</td></tr><tr><td align="left" rowspan="1" colspan="1">Productivity costs<xref ref-type="table-fn" rid="nt112">&#x02021;</xref>
</td><td align="left" rowspan="1" colspan="1">98 hr</td><td align="left" rowspan="1" colspan="1">3131</td><td align="left" rowspan="1" colspan="1">114 hr</td><td align="left" rowspan="1" colspan="1">3735</td><td align="left" rowspan="1" colspan="1">604</td><td align="left" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" rowspan="1" colspan="1">Total societal costs</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">5647</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6289</td><td align="left" rowspan="1" colspan="1">641</td><td align="left" rowspan="1" colspan="1">0.63</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt110"><label/><p>&#x0002a;General practitioner costs consist of telephonic contacts, office visits and home visits.</p></fn><fn id="nt111"><label>&#x02020;</label><p>Volumes of drugs represent percentage of patients.</p></fn><fn id="nt112"><label>&#x02021;</label><p>Volumes of productivity costs are number of hours of absence from work.</p></fn></table-wrap-foot></table-wrap><p>Patients in the Internet group reported 114 hours of absence from work compared to 98 hours for patients in the usual care group. The 16 hours difference in absenteeism was estimated to be equivalent to $604 (95&#x00025; CI, $&#x02212;1430 to $2637) in monetary terms. The difference in societal costs (i.e. health care costs plus costs due to absenteeism) was therefore estimated at $641 (95&#x00025; CI, $&#x02212;1957 to $3240) in favor of usual care.</p></sec><sec id="s3c"><title>Cost-utility analysis</title><p>The estimates of the cost differences and QALY differences were both not-statistically significant. The cost-utility ratio, based on these point estimates, was $26700 per QALY. The probability that Internet-based self-management was both more effective and less costly than usual care (dominant) was 30&#x00025;. The probability that it was less effective, but more costly (dominated) was 10&#x00025; (<xref ref-type="fig" rid="pone-0027108-g001">figure 1</xref>). Due to statistical uncertainty of both costs and QALYs, the probability that Internet-based self-management is cost-effective compared to usual care depends on the willingness-to-pay per QALY. This probability was 62&#x00025; at $50000 per QALY and 74&#x00025; at $100000 per QALY (<xref ref-type="fig" rid="pone-0027108-g001">figure 1</xref> and <xref ref-type="fig" rid="pone-0027108-g002">2</xref>).</p><p>From a health care perspective, the lower health care costs result in a cost-utility ratio of $1500 per QALY. The probability that Internet-based self-management is cost-effective from a health care perspective was 82&#x00025; at $50000 per QALY and 86&#x00025; at $100000 per QALY (<xref ref-type="fig" rid="pone-0027108-g001">figure 1</xref> and <xref ref-type="fig" rid="pone-0027108-g002">2</xref>).</p><p>QALYs gained, based on the visual analogue scale, were less than those based on the EQ-5D. The probability that Internet-based self-management is cost-effective based on visual analogue scale QALYs was 49&#x00025; and 60&#x00025; at $50000 and $100000 per QALY from a societal perspective and was 71&#x00025; and 75&#x00025; at $50000 and $100000 per QALY from a health care respectively.</p></sec></sec><sec id="s4"><title>Discussion</title><p>In this study we evaluated the cost-effectiveness of a new disease management strategy, Internet-based self-management, for patients with asthma. The QALY and cost differences, 0.024 and $ 641 respectively, between Internet based-self management and usual care were not statistically significant during a follow-up period of 1 year. Both the estimation of QALYs gained and the calculated expenses showed considerable uncertainty, which is displayed by the cost-effectiveness planes. The estimated cost-utility ratio was $26700 per QALY, which is generally considered acceptable <xref rid="pone.0027108-Rawlins1" ref-type="bibr">[32]</xref>. At a commonly cited willingness-to-pay threshold of $50000 per QALY <xref rid="pone.0027108-Eichler1" ref-type="bibr">[31]</xref> the Internet-based self-management intervention had a probability of 62&#x00025; and 82&#x00025; to be cost-effective compared to usual care from a societal perspective and health care perspective, respectively.</p><p>We have previously shown substantial and statistically significant clinical effects in favor of Internet-based self-management with regard to asthma related quality of life, asthma control and lung function <xref rid="pone.0027108-VanderMeer1" ref-type="bibr">[13]</xref>, <xref rid="pone.0027108-Juniper2" ref-type="bibr">[33]</xref>. Although the utility outcomes presented in the current study point in the same direction (i.e. in favor of Internet-based self-management) as the clinical outcomes, their statistical significance is less evident. There are two main reasons that may explain this finding. First, generic quality of life measures, such as the EQ-5D, must be distinguished from disease-specific quality of life measures, such as the Asthma Quality of Life Questionnaire <xref rid="pone.0027108-Juniper2" ref-type="bibr">[33]</xref>. The latter is well known to be responsive to change <xref rid="pone.0027108-RuttenvanMlken1" ref-type="bibr">[21]</xref>. However, generic preference-based instruments may differentiate between the highest en lowest levels of asthma control, but are less able to discriminate between moderate levels <xref rid="pone.0027108-McTaggartCowan1" ref-type="bibr">[34]</xref>, <xref rid="pone.0027108-Szende1" ref-type="bibr">[35]</xref>. The baseline asthma control scores found in our primary care study population can be classified as moderately or partly controlled asthma and substantial improvements in disease-specific quality of life may have been missed by the generic instruments. Second, the absence of a statistically significant difference in our primary utility measure may reflect a lack of statistical power, since our trial was powered to detect a statistical difference in the primary outcome measure, asthma related quality of life, and not explicitly to detect differences in generic preference-based utility measures <xref rid="pone.0027108-VanderMeer1" ref-type="bibr">[13]</xref>, <xref rid="pone.0027108-ContopoulosIoannidis1" ref-type="bibr">[36]</xref>.</p><p>The intervention costs of $254 per patient were similar to intervention costs of a paper-and-pencil asthma self-management program <xref rid="pone.0027108-Schermer1" ref-type="bibr">[10]</xref>, but were half of the costs of intensive nurse-led telemonitoring in asthma reported by others <xref rid="pone.0027108-Willems2" ref-type="bibr">[11]</xref>. The costs of the technological innovation (software support, electronic spirometer, Internet and mobile phone costs) were only about 40&#x00025; of the total intervention costs. The fixed technological costs of software support constituted about one third of the intervention costs, so a considerable increase in the number of users could reduce the cost per user by one third. Moreover, the calculations were based on costs during the one-year randomized controlled trial. Asthma self-management cost-effectiveness studies with a longer time horizon have shown that intervention costs decrease after the first year <xref rid="pone.0027108-Schermer1" ref-type="bibr">[10]</xref>, <xref rid="pone.0027108-Kauppinen1" ref-type="bibr">[37]</xref>. In our study, costs for education sessions only apply to the first year, thus reducing costs in later years by about a quarter.</p><p>Differences in other health care costs should be interpreted with caution, since almost all components showed statistically non-significant differences. Only the reduction in contacts with physiotherapists were statistically significant, suggesting that patients in the Internet group with better asthma control are less in need for physiotherapy. The cost of drugs for asthma show small decreases in short-acting &#x003b2;2-agonists and inhaled corticosteroids alone, but increases in combination therapy (inhaled corticosteroids plus long-acting &#x003b2;2-agonists) and leukotriene antagonists in the self-management group. The increase in volumes and costs of asthma controller medication accompanied by a decrease in reliever medication might have contributed to improved clinical outcomes in favor of Internet-based self-management.</p><p>Our study had several limitations. First, quality adjusted life year estimates were calculated from only two follow-up measurements. More measurements would possibly have resulted in more accurate QALY estimates, but we limited the number of follow-up measures in order to minimize the awareness of participating in a clinical trial among patients in the usual care group. Second, patients were inevitably aware of the allocated group, which may have influenced their utility ratings. Therefore, the effects observed may be due to unblinding. On the other hand, the influence of unblinded groups in pragmatic trials might be regarded as part of the intervention, since all interventions implemented in daily clinical practice are not blinded. Third, our economic evaluation was limited to one year. As pointed out above a longer duration would probably have resulted in reduced intervention cost estimates after one year. It is, however, unknown how EQ-5D utility scores will progress after one year.</p><p>New cost-effective disease management strategies for asthma are required to face up to the global burden of asthma. Internet-based self-management is an innovative and effective management strategy in adults with asthma that improves clinical outcomes <xref rid="pone.0027108-VanderMeer1" ref-type="bibr">[13]</xref>. This Internet-based strategy can be as effective as current asthma care with regard to quality of life and costs are similar. Future implementation studies ought to add other quality of life measures in order to reveal potentially more subtle differences.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0027108.s001"><label>Protocol S1</label><caption><p>Trial protocol</p><p>(DOC)</p></caption><media xlink:href="pone.0027108.s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0027108.s002"><label>Checklist S1</label><caption><p>CONSORT checklist</p><p>(DOC)</p></caption><media xlink:href="pone.0027108.s002.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0027108.s003"><label>Flowchart S1</label><caption><p>CONSORT flowchart</p><p>(TIF)</p></caption><media xlink:href="pone.0027108.s003.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The SMASHING (Self-Management of Asthma Supported by Hospitals, ICT, Nurses and General Practitioners) Study Group consists of: W.J.J. Assendelft, H.A. Thiadens, Dept. of Public Health and Primary Care; M.J. Bakker, W.B. van den Hout, J. Kievit, V. van der Meer, J.K. Sont, Dept. of Medical Decision Making; A.A. Kaptein, Medical Psychology; E.R.V.M. Rikkers-Mutsaerts, Dept. of Paediatrics; K.F. Rabe, Dept. of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands; E.H. Bel, P.J. Sterk, Dept. of Pulmonology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; SB Detmar, W Otten, TNO Quality of Life, Leiden, The Netherlands; HF van Stel, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands; AC Roldaan, Dept. of Pulmonology, HAGA Hospital, The Hague, The Netherlands; JC de Jongste, Dept. of Paediatric Respiratory Medicine, Erasmus Medical Center &#x02013; Sophia's Children Hospital, Rotterdam, The Netherlands; PJ Toussaint, Dept. of Computer and Information Science, Norwegian University of Science and Technology, Trondheim, Norway.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This study was supported by grants from the governmental Netherlands Organization for Health Research and Development (<ext-link ext-link-type="uri" xlink:href="http://www.zonmw.nl">www.zonmw.nl</ext-link> grantnrs 945-04-061 and 920-03-354) and Netherlands Asthma Foundation (<ext-link ext-link-type="uri" xlink:href="http://www.astmafonds.nl">www.astmafonds.nl</ext-link> grantnr 3.4.03.45). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group><ref-list><title>References</title><ref id="pone.0027108-National1"><label>1</label><element-citation publication-type="other">
<collab>National Institutes of Health. Global initiative for asthma</collab>
<year>1995</year>
<article-title>Global strategy for asthma management and prevention.</article-title>
<comment>NIH Publication No 02-3659, updated 2006</comment>
</element-citation></ref><ref id="pone.0027108-National2"><label>2</label><element-citation publication-type="other">
<collab>National Heart Lung and Blood Institute. National Asthma Education and Prevention Program (NAEPP)</collab>
<year>2007</year>
<comment>Expert panel report 3: guidelines for the Diagnosis and Management of Asthma</comment>
</element-citation></ref><ref id="pone.0027108-Taylor1"><label>3</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taylor</surname><given-names>DR</given-names></name><name><surname>Bateman</surname><given-names>ED</given-names></name><name><surname>Boulet</surname><given-names>L-P</given-names></name><name><surname>Boushey</surname><given-names>HA</given-names></name><name><surname>Busse</surname><given-names>WW</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>A new perspective on concepts of asthma severity and control.</article-title>
<source>Eur Respir J</source>
<volume>32</volume>
<fpage>545</fpage>
<lpage>554</lpage>
<pub-id pub-id-type="pmid">18757695</pub-id></element-citation></ref><ref id="pone.0027108-Gibson1"><label>4</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Gibson</surname><given-names>PG</given-names></name><name><surname>Powell</surname><given-names>H</given-names></name><name><surname>Coughlan</surname><given-names>J</given-names></name><name><surname>Wilson</surname><given-names>AJ</given-names></name><name><surname>Abramson</surname><given-names>M</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>Self-management education and regular practitioner review for adults with asthma (Cochrane review).</article-title>
<source>The Cochrane Library, Issue 1</source>
<publisher-loc>Oxford</publisher-loc>
<publisher-name>Update Software</publisher-name>
</element-citation></ref><ref id="pone.0027108-Willems1"><label>5</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Willems</surname><given-names>DC</given-names></name><name><surname>Joore</surname><given-names>MA</given-names></name><name><surname>Hendriks</surname><given-names>JJ</given-names></name><name><surname>Wouters</surname><given-names>EF</given-names></name><name><surname>Severens</surname><given-names>JL</given-names></name></person-group>
<year>2006</year>
<article-title>Cost-effectiveness of self-management in asthma: a systematic review of peak flow monitoring interventions.</article-title>
<source>Int J Technol Assess Health Care</source>
<volume>22</volume>
<fpage>436</fpage>
<lpage>442</lpage>
<pub-id pub-id-type="pmid">16984676</pub-id></element-citation></ref><ref id="pone.0027108-Cowie1"><label>6</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cowie</surname><given-names>RL</given-names></name><name><surname>Revitt</surname><given-names>SG</given-names></name><name><surname>Underwood</surname><given-names>MF</given-names></name><name><surname>Field</surname><given-names>SK</given-names></name></person-group>
<year>1997</year>
<article-title>The effect of a peak flow-based action plan in the prevention of exacerbations of asthma.</article-title>
<source>Chest</source>
<volume>112</volume>
<fpage>1534</fpage>
<lpage>1538</lpage>
<pub-id pub-id-type="pmid">9404750</pub-id></element-citation></ref><ref id="pone.0027108-Ghosh1"><label>7</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>CS</given-names></name><name><surname>Ravindran</surname><given-names>P</given-names></name><name><surname>Joshi</surname><given-names>M</given-names></name><name><surname>Stearns</surname><given-names>SC</given-names></name></person-group>
<year>1998</year>
<article-title>Reductions in hospital use from self-management training for chronic asthmatics.</article-title>
<source>Soc Sci Med</source>
<volume>46</volume>
<fpage>1087</fpage>
<lpage>1093</lpage>
<pub-id pub-id-type="pmid">9579760</pub-id></element-citation></ref><ref id="pone.0027108-Lahdensuo1"><label>8</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lahdensuo</surname><given-names>A</given-names></name><name><surname>Haahtela</surname><given-names>T</given-names></name><name><surname>Herrala</surname><given-names>J</given-names></name><name><surname>Kava</surname><given-names>T</given-names></name><name><surname>Kiviranta</surname><given-names>K</given-names></name><etal/></person-group>
<year>1998</year>
<article-title>Randomised comparison of cost effectiveness of guided self management and traditional treatment of asthma in Finland.</article-title>
<source>BMJ</source>
<volume>316</volume>
<fpage>1138</fpage>
<lpage>1139</lpage>
<pub-id pub-id-type="pmid">9552954</pub-id></element-citation></ref><ref id="pone.0027108-Gallefoss1"><label>9</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gallefoss</surname><given-names>F</given-names></name><name><surname>Bakke</surname><given-names>PS</given-names></name></person-group>
<year>2001</year>
<article-title>Cost-effectiveness of self-management in asthmatics: A 1-yr follow-up randomised, controlled trial.</article-title>
<source>Eur Respir J</source>
<volume>17</volume>
<fpage>206</fpage>
<lpage>213</lpage>
<pub-id pub-id-type="pmid">11334121</pub-id></element-citation></ref><ref id="pone.0027108-Schermer1"><label>10</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schermer</surname><given-names>TR</given-names></name><name><surname>Thoonen</surname><given-names>BP</given-names></name><name><surname>Van den Boom</surname><given-names>G</given-names></name><name><surname>Akkermans</surname><given-names>RP</given-names></name><name><surname>Grol</surname><given-names>RP</given-names></name><etal/></person-group>
<year>2002</year>
<article-title>Randomized controlled economic evaluation of asthma self-management in primary health care.</article-title>
<source>Am J Respir Crit Care Med</source>
<volume>166</volume>
<fpage>1062</fpage>
<lpage>1072</lpage>
<pub-id pub-id-type="pmid">12379549</pub-id></element-citation></ref><ref id="pone.0027108-Willems2"><label>11</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Willems</surname><given-names>DCM</given-names></name><name><surname>Joore</surname><given-names>MA</given-names></name><name><surname>Hendriks</surname><given-names>JJE</given-names></name><name><surname>Wouters</surname><given-names>EFM</given-names></name><name><surname>Severens</surname><given-names>JL</given-names></name></person-group>
<year>2007</year>
<article-title>Cost-effectiveness of a nurse-led telemonitoring intervention base on peak expiratory flow measurements in asthmatics: results of a randomised controlled trial.</article-title>
<source>Cost Eff Resour Alloc</source>
<volume>5</volume>
<fpage>10</fpage>
<pub-id pub-id-type="pmid">17662113</pub-id></element-citation></ref><ref id="pone.0027108-Jones1"><label>12</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jones</surname><given-names>A</given-names></name><name><surname>Pill</surname><given-names>R</given-names></name><name><surname>Adams</surname><given-names>S</given-names></name></person-group>
<year>2000</year>
<article-title>Qualitative study of views of health professionals and patients on guided self management plans for asthma.</article-title>
<source>BMJ</source>
<volume>321</volume>
<fpage>1507</fpage>
<lpage>1510</lpage>
<pub-id pub-id-type="pmid">11118179</pub-id></element-citation></ref><ref id="pone.0027108-VanderMeer1"><label>13</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van der Meer</surname><given-names>V</given-names></name><name><surname>Bakker</surname><given-names>MJ</given-names></name><name><surname>Van den Hout</surname><given-names>WB</given-names></name><name><surname>Rabe</surname><given-names>KF</given-names></name><name><surname>Sterk</surname><given-names>PJ</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Internet-Based Self-Management plus Education Compared to Usual Care in Asthma: a Randomized Controlled Trial.</article-title>
<source>Ann Intern Med</source>
<volume>151</volume>
<fpage>110</fpage>
<lpage>120</lpage>
<pub-id pub-id-type="pmid">19620163</pub-id></element-citation></ref><ref id="pone.0027108-Rasmussen1"><label>14</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rasmussen</surname><given-names>LM</given-names></name><name><surname>Phanareth</surname><given-names>K</given-names></name><name><surname>Nolte</surname><given-names>H</given-names></name><name><surname>Backer</surname><given-names>V</given-names></name></person-group>
<year>2005</year>
<article-title>Internet-based monitoring of asthma: a long-term, randomized clinical study of 300 asthmatic subjects.</article-title>
<source>J Allergy Clin Immunol</source>
<volume>115</volume>
<fpage>1137</fpage>
<lpage>1142</lpage>
<pub-id pub-id-type="pmid">15940125</pub-id></element-citation></ref><ref id="pone.0027108-Chan1"><label>15</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chan</surname><given-names>DS</given-names></name><name><surname>Callahan</surname><given-names>CW</given-names></name><name><surname>Hatch-Pigott</surname><given-names>VB</given-names></name><name><surname>Lawless</surname><given-names>A</given-names></name><name><surname>Proffitt</surname><given-names>L</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Internet-based home monitoring and education of children with asthma is comparable to ideal office-based care: results of a 1-year asthma in-home monitoring trial.</article-title>
<source>Pediatrics</source>
<volume>119</volume>
<fpage>569</fpage>
<lpage>578</lpage>
<pub-id pub-id-type="pmid">17332210</pub-id></element-citation></ref><ref id="pone.0027108-Jan1"><label>16</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jan</surname><given-names>RL</given-names></name><name><surname>Wang</surname><given-names>JY</given-names></name><name><surname>Huang</surname><given-names>MC</given-names></name><name><surname>Tseng</surname><given-names>SM</given-names></name><name><surname>Su</surname><given-names>HJ</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>An Internet-based interactive telemonitoring system for improving childhood asthma outcomes in Taiwan.</article-title>
<source>Telemed J E Health</source>
<volume>13</volume>
<fpage>257</fpage>
<lpage>268</lpage>
<pub-id pub-id-type="pmid">17603828</pub-id></element-citation></ref><ref id="pone.0027108-Lamberts1"><label>17</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Lamberts</surname><given-names>H</given-names></name><name><surname>Wood</surname><given-names>M</given-names></name></person-group>
<year>1987</year>
<source>International Classification of Primary Care</source>
<publisher-loc>Oxford</publisher-loc>
<publisher-name>Oxford University Press</publisher-name>
</element-citation></ref><ref id="pone.0027108-Juniper1"><label>18</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Juniper</surname><given-names>EF</given-names></name><name><surname>O'Byrne</surname><given-names>PM</given-names></name><name><surname>Guyatt</surname><given-names>GH</given-names></name><name><surname>Ferrie</surname><given-names>PJ</given-names></name><name><surname>King</surname><given-names>DR</given-names></name></person-group>
<year>1999</year>
<article-title>Development and validation of a questionnaire to measure asthma control.</article-title>
<source>Eur Respir J</source>
<volume>14</volume>
<fpage>902</fpage>
<lpage>907</lpage>
<pub-id pub-id-type="pmid">10573240</pub-id></element-citation></ref><ref id="pone.0027108-The1"><label>19</label><element-citation publication-type="journal">
<collab>The EuroQol Group</collab>
<year>1990</year>
<article-title>EuroQol &#x02013; a new facility for the measurement of health-related quality of life.</article-title>
<source>Health Policy</source>
<volume>16</volume>
<fpage>199</fpage>
<lpage>208</lpage>
<pub-id pub-id-type="pmid">10109801</pub-id></element-citation></ref><ref id="pone.0027108-Dolan1"><label>20</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dolan</surname><given-names>P</given-names></name></person-group>
<year>1997</year>
<article-title>Modeling valuations for EuroQol health states.</article-title>
<source>Med Care</source>
<volume>35</volume>
<fpage>1095</fpage>
<lpage>1108</lpage>
<pub-id pub-id-type="pmid">9366889</pub-id></element-citation></ref><ref id="pone.0027108-RuttenvanMlken1"><label>21</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rutten-van M&#x000f6;lken</surname><given-names>MPMH</given-names></name><name><surname>Custers</surname><given-names>F</given-names></name><name><surname>Van Doorslaer</surname><given-names>EKA</given-names></name><name><surname>Jansen</surname><given-names>CCM</given-names></name><name><surname>Heurman</surname><given-names>L</given-names></name><etal/></person-group>
<year>1995</year>
<article-title>Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life.</article-title>
<source>Eur Respir J</source>
<volume>8</volume>
<fpage>888</fpage>
<lpage>898</lpage>
<pub-id pub-id-type="pmid">7589374</pub-id></element-citation></ref><ref id="pone.0027108-Stiggelbout1"><label>22</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stiggelbout</surname><given-names>AM</given-names></name><name><surname>Eijkemans</surname><given-names>MJ</given-names></name><name><surname>Kiebert</surname><given-names>GM</given-names></name><name><surname>Kievit</surname><given-names>J</given-names></name><name><surname>Leer</surname><given-names>JW</given-names></name><etal/></person-group>
<year>1996</year>
<article-title>The &#x02018;utility&#x02019;of the visual analog scale in medical decision making and technology assessment. Is it an alternative to the time trade-off?</article-title>
<source>Int J Technol Assess Health Care</source>
<volume>12</volume>
<fpage>291</fpage>
<lpage>298</lpage>
<pub-id pub-id-type="pmid">8707502</pub-id></element-citation></ref><ref id="pone.0027108-Briggs1"><label>23</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Briggs</surname><given-names>A</given-names></name><name><surname>Clark</surname><given-names>T</given-names></name><name><surname>Wolstenholme</surname><given-names>J</given-names></name><name><surname>Clarke</surname><given-names>P</given-names></name></person-group>
<year>2003</year>
<article-title>Missing&#x02026; presumed at random: cost-analysis of incomplete data.</article-title>
<source>Health Econ</source>
<volume>12</volume>
<fpage>377</fpage>
<lpage>392</lpage>
<pub-id pub-id-type="pmid">12720255</pub-id></element-citation></ref><ref id="pone.0027108-VanBuuren1"><label>24</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van Buuren</surname><given-names>S</given-names></name><name><surname>Boshuizen</surname><given-names>HC</given-names></name><name><surname>Knook</surname><given-names>DL</given-names></name></person-group>
<year>1999</year>
<article-title>Multiple imputation of missing blood pressure covariates in survival analysis.</article-title>
<source>Stat Med</source>
<volume>18</volume>
<fpage>681</fpage>
<lpage>694</lpage>
<pub-id pub-id-type="pmid">10204197</pub-id></element-citation></ref><ref id="pone.0027108-Oostenbrink1"><label>25</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Oostenbrink</surname><given-names>JB</given-names></name><name><surname>Koopmanschap</surname><given-names>MA</given-names></name><name><surname>Rutten</surname><given-names>FFH</given-names></name></person-group>
<year>2004</year>
<source>Manual for cost analyses, methods and standard prices for economic evaluations in health care</source>
<publisher-loc>[In Dutch.] Amstelveen</publisher-loc>
<publisher-name>Dutch Health Insurance Executive Board</publisher-name>
</element-citation></ref><ref id="pone.0027108-Dutch1"><label>26</label><element-citation publication-type="other">
<collab>Dutch Health Insurance Executive Board</collab>
<year>2007</year>
<article-title>Pharmacotherapeutic Compass [in Dutch].</article-title>
<comment>Available: <ext-link ext-link-type="uri" xlink:href="http://www.fk.cvz.nl">www.fk.cvz.nl</ext-link>. Accessed 2007 November</comment>
</element-citation></ref><ref id="pone.0027108-Statistics1"><label>27</label><element-citation publication-type="other">
<collab>Statistics Netherlands</collab>
<year>2008</year>
<article-title>Consumer price index.</article-title>
<comment>Available: <ext-link ext-link-type="uri" xlink:href="http://www.cbs.nl">www.cbs.nl</ext-link>. Accessed 2008 July 2</comment>
</element-citation></ref><ref id="pone.0027108-OECD1"><label>28</label><element-citation publication-type="journal">
<collab>OECD</collab>
<year>2008</year>
<article-title>Purchasing Power Parities (PPPs) for OECD Countries 1980&#x02013;2006.</article-title>
<comment>Available: <ext-link ext-link-type="uri" xlink:href="http://www.oecd.org/dataoecd/61/56/39653523.xls">www.oecd.org/dataoecd/61/56/39653523.xls</ext-link>. Accessed 2008 July 2</comment>
</element-citation></ref><ref id="pone.0027108-Rubin1"><label>29</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Rubin</surname><given-names>DB</given-names></name></person-group>
<year>1987</year>
<source>Multiple imputation for non response in surveys</source>
<publisher-loc>New York</publisher-loc>
<publisher-name>J Wiley</publisher-name>
</element-citation></ref><ref id="pone.0027108-Stinnett1"><label>30</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stinnett</surname><given-names>AA</given-names></name><name><surname>Mullahy</surname><given-names>J</given-names></name></person-group>
<year>1998</year>
<article-title>Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis.</article-title>
<source>Med Decis Making</source>
<volume>18</volume>
<fpage>S68</fpage>
<lpage>S80</lpage>
<pub-id pub-id-type="pmid">9566468</pub-id></element-citation></ref><ref id="pone.0027108-Eichler1"><label>31</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eichler</surname><given-names>HG</given-names></name><name><surname>Kong</surname><given-names>SX</given-names></name><name><surname>Gerth</surname><given-names>WC</given-names></name><name><surname>Mavros</surname><given-names>P</given-names></name><name><surname>Jonsson</surname><given-names>B</given-names></name></person-group>
<year>2004</year>
<article-title>Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?</article-title>
<source>Value Health</source>
<volume>7</volume>
<fpage>518</fpage>
<lpage>528</lpage>
<pub-id pub-id-type="pmid">15367247</pub-id></element-citation></ref><ref id="pone.0027108-Rawlins1"><label>32</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rawlins</surname><given-names>MD</given-names></name><name><surname>Culyer</surname><given-names>AJ</given-names></name></person-group>
<year>2004</year>
<article-title>National Institute for Clinical Excellence and its value judgments.</article-title>
<source>BMJ</source>
<volume>329</volume>
<fpage>224</fpage>
<lpage>227</lpage>
<pub-id pub-id-type="pmid">15271836</pub-id></element-citation></ref><ref id="pone.0027108-Juniper2"><label>33</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Juniper</surname><given-names>EF</given-names></name><name><surname>Guyatt</surname><given-names>GH</given-names></name><name><surname>Ferrie</surname><given-names>PJ</given-names></name><name><surname>Griffith</surname><given-names>LE</given-names></name></person-group>
<year>1993</year>
<article-title>Measuring quality of life in asthma.</article-title>
<source>Am Rev Respir Dis</source>
<volume>147</volume>
<fpage>832</fpage>
<lpage>838</lpage>
<pub-id pub-id-type="pmid">8466117</pub-id></element-citation></ref><ref id="pone.0027108-McTaggartCowan1"><label>34</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McTaggart-Cowan</surname><given-names>HM</given-names></name><name><surname>Marra</surname><given-names>CA</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Brzazier</surname><given-names>JE</given-names></name><name><surname>Kopec</surname><given-names>JA</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status.</article-title>
<source>Qual Life Res</source>
<volume>17</volume>
<fpage>453</fpage>
<lpage>462</lpage>
<pub-id pub-id-type="pmid">18274882</pub-id></element-citation></ref><ref id="pone.0027108-Szende1"><label>35</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Szende</surname><given-names>A</given-names></name><name><surname>Svensson</surname><given-names>K</given-names></name><name><surname>St&#x000e5;hl</surname><given-names>E</given-names></name><name><surname>M&#x000e9;sz&#x000e1;ros</surname><given-names>A</given-names></name><name><surname>Berta</surname><given-names>GY</given-names></name></person-group>
<year>2004</year>
<article-title>Psychometric and utility-based measures of health status of asthmatic patients with different disease control level.</article-title>
<source>Pharmacoeconomics</source>
<volume>22</volume>
<fpage>537</fpage>
<lpage>547</lpage>
<pub-id pub-id-type="pmid">15217309</pub-id></element-citation></ref><ref id="pone.0027108-ContopoulosIoannidis1"><label>36</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Contopoulos-Ioannidis</surname><given-names>DG</given-names></name><name><surname>Karvouni</surname><given-names>A</given-names></name><name><surname>Kouri</surname><given-names>I</given-names></name><name><surname>Ioannidis</surname><given-names>JPA</given-names></name></person-group>
<year>2009</year>
<article-title>Reporting and interpretation of SF-36 outcomes in randomised trials: systematic review.</article-title>
<source>BMJ</source>
<volume>338</volume>
<fpage>a3006</fpage>
<pub-id pub-id-type="pmid">19139138</pub-id></element-citation></ref><ref id="pone.0027108-Kauppinen1"><label>37</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kauppinen</surname><given-names>R</given-names></name><name><surname>Vilkka</surname><given-names>V</given-names></name><name><surname>Sintonen</surname><given-names>H</given-names></name><name><surname>Klaukka</surname><given-names>T</given-names></name><name><surname>Tukiainen</surname><given-names>H</given-names></name></person-group>
<year>2001</year>
<article-title>Long-term economic evaluation of intensive patient education during the first treatment year in newly diagnosed adult asthma.</article-title>
<source>Respir Med</source>
<volume>95</volume>
<fpage>56</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="pmid">11207019</pub-id></element-citation></ref></ref-list></back></article>